CClinicalTrials.gg
RecruitingNCT03875989TAPPUpdated Aug 29, 2023

Vaginal Native Tissues Repair for Pelvic Organ Prolapse

An interventional study of Anterior colporraphy and vaginal patch plastron in Prolapse, Vaginal, sponsored by University Hospital, Limoges. Recruiting at 9 sites in France. Open to female participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2023-08-29.

Sponsored by University Hospital, Limoges · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year ago, but the record still lists the study as recruiting.
  • Started Sep 2019; still recruiting 7 years later.
Phase
Not applicable
Study type
Interventional
Enrollment
214
Allocation
Randomized
Ages
50 Years and older
Sex
Female
01

Study summary

The aim of the study is to assess at one year the effectiveness of the vaginal patch plastron in comparison of the anterior colporraphy through a combined definition of success: anatomic and functional.

Read the detailed description

Pelvic organ prolapse is usually the result of loss of pelvic support. It is widely accepted that 50% of women after 50 years old will develop prolapse, evaluated through the POPQ Classification . Pelvic organ prolapse cause significant psychological distress and negatively affect quality of life. Among the surgery for prolapse, the cystocele cureis is the most frequent (67.7%). Native tissue cystocele repairs is the cornerstone of prolapse surgery especially since the learned societies (Food and Drug Administration, Haute Autorité de Santé, Collège National des Gynécologues-Obstétriciens Français) warned clinicians and patients about serious mesh related complications. In France, 41.5% of vaginal cystocele repair are with native tissue. The main surgeries are anterior colporraphy and vaginal patch plastron, used in routine in our center with re-intervention rates less than 4% at one year. Rate of success of native tissue cystocele repair are heterogeneous, depending on the design of studies and definition of outcomes. A prospective study find a success rate at 35% of the anterior colporraphy based on a combined definition, anatomic and functional as recommended recently. However the definition of anatomic was strict (POPQ\<2), while it seems that the best definition of anatomic success is "no prolapse among the hymen", that is to say aAa and Ba points \<0.

We think that the vaginal patch plastron will have a better anatomic and functional success comparatively to the anterior colporraphy as it corrects median cystoceles by a vaginal strip as well as lateral cystoceles by the bilateral paravaginal suspension.

The description of the two surgeries will be standardized between all the surgeons. We will compare the anterior colporraphy consisting in bladder median support by retensioning Halban fascia with colpectomy to the vaginal patch plastron consisting in making a vaginal strip attached to the bladder combined with suspension by fixation of the vaginal strip to the tendinous arch of the pelvic fascia.

Patients will be blind of their surgery. They will have a follow-up visit 45 days after the surgery to evaluate the post- operative complications according to the Clavien-Dindo classification. They will have phone call at 4 and 8 months after the surgery to make sure they've not suffered for complications. At last, they will have a follow-up visit 1 year after the surgery by an independent assessor blind of the surgery to evaluate the primary outcome (anatomic and functional success).

02

Conditions studied

  • Prolapse, Vaginal

Keywords

  • Prolapse
  • Vaginal native tissues repair
  • Pelvic organ
03

In context

Uterine Prolapse

111 studies on the registry are indexed under Uterine Prolapse; 20 are open to participants now.

This study's planned enrollment of 214 is above the median of 70 across 81 interventional studies indexed under Uterine Prolapse.

Browse Uterine Prolapse studies →

Lead sponsor

University Hospital, Limoges is the lead sponsor of 255 studies on the registry; 36 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Patient at 50 years of age or older
  • Symptomatic primary prolapse of the anterior vaginal wall defined by Aa and/or Ba points ≥0 according to the POP-Q system
  • A positive response to the question "Do you usually have a bulge or something falling out that you can see or feel in your vaginal area?" (question 3 of the PFDI-20)
  • Able to give informed consent
  • Performans Status score ≤ 2

Exclusion criteria

Exclusion Criteria:

  • Patient with need for surgical treatment for myorraphy of levator ani muscles
  • Patient with previous surgical cystocele repair.
  • Patient with evolving gynaecologic cancer.
  • Pregnancy or wish for future pregnancy, lactating woman.
  • Inability to participate in study follow-up or to provide informed consent.
  • Lack of social insurance .
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
214 participants (estimated)

Study arms

  • Active comparator
    Arm A

    Procedure: Anterior colporraphy

  • Experimental
    Arm B

    Procedure: vaginal patch plastron

Interventions

  • ProcedureAnterior colporraphy

    It will be delimitate a rectangular vaginal strip which will be isolated from the anterior colpocele. The superior edge of the strip is placed 2 cm from the urethral orifice. After lateral vesico-vaginal dissection, the paravesical fossae will be wide opened to repair the tendinous arches. The vaginal plastron will be fixed to the tendinous arch of the pelvic fascia by 3 lateral stitches (anterior/ lateral/ posterior) on each side of the plastron. After, the plastron will be tensioning and the cystocele will be suspended. The closure of the vaginal wall will end the procedure.

  • Procedurevaginal patch plastron

    It will be make a midline incision of the anterior vaginal wall from the urethrovesical junction to the vaginal apex or anterior fornix. The vaginal epithelium will be separated from the underlying fibromuscular layer (Halban Fascia) after the midline incision. Midline plication of the fibromuscular layer will be obtained by interrupted horizontal stiches. The closure of the vaginal wall will end the procedure.

06

What researchers measure

Primary outcomes

  1. Rate of the prolapse surgery

    The success rate of the prolapse surgery defined by a composite of objective and subjective measures: * Anatomic success defined by Aa and Ba values \<0 in Pelvic Organ Prolapse Quantification System (POP-Q) AND * Subjective success through reliable condition-specific quality-of-life questionnaires: * A negative response to the question "Do you usually have a bulge or something falling out that you can see or feel in your vaginal area?" (question 3 of the Pelvic Floor Distress Inventory (PFDI-20)) AND * Range score of Patient Global Impression of Improvement (PGI-I) 1 or 2 AND * No need for other treatment for prolapse (surgical nor medical)

    Time frame: 1 year

Secondary outcomes

  1. Rate of the prolapse surgery

    The failure rate of the prolapse surgery defined by a composite of objective and subjective measures: * Recurrent prolapse defined by Aa and/or Ba values \> or= 0 in POP-Q OR * Subjective failure through reliable condition-specific quality-of-life questionnaires: * A positive response to the question "Do you usually have a bulge or something falling out that you can see or feel in your vaginal area?" (question 3 of the PFDI-20) OR * A PGI-I score \> 2 OR * Need of a new treatment for prolapse (surgical or medical)

    Time frame: 1 year

  2. Rate of post-operative complications

    Rate of post-operative complications according to the Clavien-Dindo classification 45 days after the surgery by the patient's surgeon (not blinded)

    Time frame: 45 Days

  3. Sexual function

    The sexual function improvement will be evaluated by the difference in PISQ 12 score (condition-specific quality-of-life questionnaire) between the inclusion and one year after the surgery for sexually active women

    Time frame: 1 year

  4. Rate of the prolapse surgery

    The failure rate of the prolapse surgery defined by a composite of objective and subjective measures: * Recurrent prolapse defined by Aa and/or Ba values \> or= 0 in POP-Q OR * Subjective failure through reliable condition-specific quality-of-life questionnaires: * A positive response to the question "Do you usually have a bulge or something falling out that you can see or feel in your vaginal area?" (question 3 of the PFDI-20) OR * A PGI-I score \> 2 OR * Need of a new treatment for prolapse (surgical or medical)

    Time frame: 2 years

  5. Rate of the prolapse surgery

    The failure rate of the prolapse surgery defined by a composite of objective and subjective measures: * Recurrent prolapse defined by Aa and/or Ba values \> or= 0 in POP-Q OR * Subjective failure through reliable condition-specific quality-of-life questionnaires: * A positive response to the question "Do you usually have a bulge or something falling out that you can see or feel in your vaginal area?" (question 3 of the PFDI-20) OR * A PGI-I score \> 2 OR * Need of a new treatment for prolapse (surgical or medical)

    Time frame: 3 years

07

Study locations

9 of 9 sites recruiting
  • CHU de Bordeaux
    Bordeaux, 33000, France
    • Claude HOCKE, MD · Contact · claude.hocke@chu-bordeaux.fr
    • Claude HOCKE, MD · Principal investigator
    • Mathilde CORET, MD · Sub investigator
    • Jean-Luc BRUN, MD · Sub investigator
    • Géraldine CHAUVIN, MD · Sub investigator
    Recruiting
  • CH de Brive
    Brive-la-Gaillarde, 19100, France
    • Christelle MESNARD, MD · Contact · mesnardc@yahoo.fr
    • Christelle MESNARD, MD · Principal investigator
    • Tristan GAUTHIER, MD · Sub investigator
    • Dimitrios HARISIS, MD · Sub investigator
    Recruiting
  • CHU de Clermont Ferrand
    Clermont-Ferrand, 63100, France
    Recruiting
  • CH de Gueret
    Guéret, 23000, France
    • Yves AUBARD, MD · Contact · yves.aubard@chu-limoges.fr
    • Yves AUBARD, MD · Principal investigator
    • Aymeline LACORRE, MD · Sub investigator
    Recruiting
  • CHU de Limoges
    Limoges, 87000, France
    • Aymeline LACORRE, MD · Contact · aymeline.lacorre@chu-limoges.fr
    • Tristan GAUTHIER, MD · Contact · tristan.gauthier@chu-limoges.fr
    • Aymeline LACORRE, MD · Principal investigator
    • Tristan GAUTHIER, MD · Sub investigator
    • Yves AUBARD, MD · Sub investigator
    • Hugues CALY, MD · Sub investigator
    • Maxime LEGROS, MD · Sub investigator
    • François MARGUERITTE, MD · Sub investigator
    Recruiting
  • CHU de Saint-Etienne
    Saint-Étienne, 42000, France
    Recruiting
  • CHU de Toulouse - Paule de Viguier
    Toulouse, 31059, France
    • Hélène POL, MD · Contact · helene.pol@chu-toulouse.fr
    • Fabien VIDAL, MD · Principal investigator
    • Yann TANGUY LE GAC, MD · Sub investigator
    • Géraldine CARTRON, MD · Sub investigator
    • Martin BAUJAT, MD · Sub investigator
    Recruiting
  • CHU de Toulouse - Rangueil
    Toulouse, 31400, France
    • Elodie CHANTALAT, MD · Contact · chantalat.e@chu-toulouse.fr
    • Elodie CHANTALAT, MD · Principal investigator
    • Jacques RIMAILHO, MD · Sub investigator
    • Stéphanie MOTTON, MD · Sub investigator
    • Marc SOULE-THOLY, MD · Sub investigator
    Recruiting
  • CH de Tulle
    Tulle, 19000, France
    Recruiting
08

References and documents

Publications

  • Lacorre A, Vidal F, Campagne-Loiseau S, Marin B, Aubard Y, Siegerth F, Mesnard C, Chantalat E, Hocke C, Gauthier T. Protocol for a randomized controlled trial to assess two procedures of vaginal native tissue repair for pelvic organ prolapse at the time of the questioning on vaginal prosthesis: the TAPP trial. Trials. 2020 Jul 8;21(1):624. doi: 10.1186/s13063-020-04512-x. PubMed 32641096 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03875989
Lead sponsor
University Hospital, Limoges
Responsible party
Sponsor
First posted
Mar 15, 2019
Start date
Sep 27, 2019
Primary completion
Sep 27, 2025 (estimated)
Completion
Mar 27, 2028 (estimated)
Last update
Aug 29, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion